查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1801164

多发性骨髓瘤药物市场规模、份额、趋势及预测（按疗法、药物类型、最终用户、配销通路和地区），2025 年至 2033 年

Multiple Myeloma Drugs Market Size, Share, Trends and Forecast by Therapy, Drug Type, End User, Distribution Channel, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 119 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球多发性骨髓瘤药物市场规模达234.6亿美元。展望未来， IMARC Group预测，到2033年，该市场规模将达到368.6亿美元，2025-2033年期间的复合年增长率为4.89%。目前，北美占据市场主导地位，2024年其市占率将超过40.7%。这种主导地位得益于先进的医疗基础设施、创新疗法的广泛采用以及对肿瘤学研究的大量投入。主要製药公司的布局和优惠的报销政策进一步提升了该地区多发性骨髓瘤药物的市场份额。

精准医疗方法和生物标记驱动治疗策略的兴起推动了市场发展。製药公司不断增加对新药研发的投资，包括双特异性抗体和下一代蛋白酶体抑制剂，这正在拓展治疗选择。全球范围内临床试验设计的改进和适应性监管途径的建立正在加速创新药物的上市时间。此外，诊断影像和基因组学的进步改进了疾病分类，从而实现了更个人化的治疗方案。数位健康技术在监测患者反应和提高依从性方面的日益普及也发挥着重要作用。生物技术公司和研究机构之间的策略合作进一步支持了治疗领域的持续进步。

在美国，多发性骨髓瘤药物市场的成长得益于联邦政府对肿瘤学研究的大力资助以及先进的医疗基础设施。包括CAR-T细胞疗法和抗体药物偶联物在内的突破性疗法的高采用率正在加速市场渗透。拥有强大商业化能力的大型製药公司的存在支持了药物的快速部署。此外，医疗保险和私人保险公司提供的优惠报销框架提高了患者获得昂贵治疗的管道。人口老化和预期寿命的延长也导致了疾病发生率的上升。例如，在2025年5月的ADVANCE试验中，包含达雷妥尤单抗的四药联合疗法（DKRd）显示出对新诊断的多发性骨髓瘤患者的疗效改善。与标准KRd方案相比，DKRd实现了更高的MRD阴性率（59% vs. 36%）和更好的近33个月无恶化存活期（86% vs. 79%），且毒性反应没有显着增加。这些发现支持 DKRd 作为潜在的新护理标准，使一些患者能够推迟干细胞移植，并强调了 MRD 阴性在指导治疗决策中的重要性。

多发性骨髓瘤药物市场趋势：

血液系统癌症负担加重，推动药物需求

全球血液系统恶性肿瘤发生率的不断上升，对多发性骨髓瘤药物市场产生了重大影响。 2022年，这类癌症占所有确诊癌症病例的6.6%，占相关死亡人数的7.2%，凸显了标靶治疗的迫切需求。由于多发性骨髓瘤主要源自于基因异常，其治疗需要多学科方法，包括免疫调节药物、化学治疗、放射治疗和干细胞移植。血小板输注在控制副作用方面也扮演重要角色。随着早期检测水准的提高，更多患者有资格接受先进的治疗。全球医疗保健系统面临着提供有效疗法的压力，这加速了骨髓瘤特异性药物的创新，并增加了对骨髓瘤特异性药物的投资，从而促进了多发性骨髓瘤药物市场的乐观前景。

科技进步加速治疗创新

技术进步正在改变多发性骨髓瘤的治疗，尤其是透过基于microRNA的疗法和奈米药物等创新。这些平台能够精准靶向恶性细胞，同时最大限度地减少对健康组织的损害。一个典型的例子是Ardena位于荷兰奥斯的奈米药物工厂，该工厂投资2,000万欧元，于2024年11月获得GMP认证。该工厂支持脂质和聚合物奈米颗粒的复杂製造，这些奈米颗粒是将大分子药物输送到骨髓并引发抗肿瘤反应的关键载体。这些创新不仅可以提高治疗效果，还可以透过减少併发症来降低长期医疗成本。随着製药公司不断拓展其奈米技术能力，这些发展预计将在推动多发性骨髓瘤药物市场成长方面发挥至关重要的作用。

增加生物疗法的采用和医疗支出

人们对生物疗法日益增长的认识正在重塑多发性骨髓瘤患者的治疗偏好。这些药物利用免疫系统来识别并清除癌细胞，提供了一种比传统疗法侵入性更小、通常更有效的替代方案。患者越来越倾向于选择那些标靶作用机制强、全身副作用较少的疗法。同时，全球医疗保健支出不断增长（据报道，2021年全球医疗保健支出达9.8兆美元，相当于全球GDP的10.3%），使得这些先进疗法的可及性更加广泛。加之製药业不断增长的研究预算，生物疗法在已开发市场和新兴市场都越来越受欢迎。预计这一转变将在未来几年显着促进多发性骨髓瘤药物市场的扩张。

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：产品线评估/临床试验产品/临床开发

  • PegIntron（聚乙二醇干扰素α-2b）
  • 泊马度胺
  • 坦尼匹霉素（KOS-953）
  • MLN 9708
  • SRT-501- 012
  • BHQ880
  • 帕比司他
  • ZIO-101
  • VEGF-Trap（阿柏西普）
  • 地舒单抗
  • 哌利福星
  • 克力美德 (CC-5013)
  • 罗米地辛
  • Plitidepsin（阿普利丁）
  • 替西罗莫司（Torisel）
  • 索拉非尼
  • 贝伐单抗

第六章：全球多发性骨髓瘤药物市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第七章：市场区隔：依疗法

  • 标靶治疗
  • 生物治疗
  • 化疗
  • 其他的

第八章：市场区隔：依药物类型

  • 免疫调节药物
  • 蛋白酶体抑制剂
  • 组蛋白去乙酰化酶抑制剂
  • 单株抗体药物
  • 类固醇
  • 其他的

第九章：市场区隔：依最终用户

  • 男士
  • 女性

第十章：市场区隔：按配销通路

  • 医院药房
  • 零售药局
  • 网路药局
  • 其他的

第 11 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 12 章：SWOT 分析

第 13 章：价值链分析

第 14 章：波特五力分析

第 15 章：价格指标

第 16 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Amgen Inc.
    • Bristol Myers Squibb
    • Daiichi Sankyo Co.
    • Sanofi-Aventis Groupe (Genzyme Corporation)
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Novartis International AG
    • Pfizer Inc.
    • PHARMA MAR, SA
    • Takeda Pharmaceutical Company Limited.
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112025A2169

The global multiple myeloma drugs market size was valued at USD 23.46 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 36.86 Billion by 2033, exhibiting a CAGR of 4.89% during 2025-2033. North America currently dominates the market, holding a significant market share of over 40.7% in 2024. This dominance is driven by advanced healthcare infrastructure, high adoption of innovative therapies, and substantial investment in oncology research. The presence of key pharmaceutical companies and favorable reimbursement policies further fuel multiple myeloma drugs market share in the region.

The market is propelled by an upsurge in precision medicine approaches and biomarker-driven treatment strategies. Increasing investments by pharmaceutical companies in novel drug discovery, including bispecific antibodies and next-generation proteasome inhibitors, are expanding therapeutic options. Enhanced clinical trial designs and adaptive regulatory pathways in global regions are accelerating time-to-market for innovative drugs. Moreover, improvements in diagnostic imaging and genomics have refined disease classification, enabling more personalized treatment regimens. The growing incorporation of digital health technologies to monitor patient response and improve adherence also plays a significant role. Strategic collaborations among biotech firms and research institutions further support ongoing therapeutic advancements.

In the United States, the multiple myeloma drugs market growth is driven by robust federal funding for oncology research and the presence of an advanced healthcare infrastructure. The high adoption rate of breakthrough therapies, including CAR-T cell therapies and antibody-drug conjugates, is accelerating market penetration. The presence of major pharmaceutical players with strong commercialization capabilities supports rapid drug deployment. Additionally, favorable reimbursement frameworks through Medicare and private insurers improve access to costly treatments. An aging population and increasing life expectancy also contribute to rising disease incidence. For instance, in May 2025, a four-drug combination (DKRd) including daratumumab showed improved outcomes for newly diagnosed multiple myeloma patients in the ADVANCE trial. Compared to the standard KRd regimen, DKRd achieved higher MRD-negativity (59% vs. 36%) and better progression-free survival at nearly 33 months (86% vs. 79%), without significantly increased toxicity. These findings support DKRd as a potential new standard of care, enabling some patients to defer stem cell transplants and highlighting the importance of MRD-negativity in guiding treatment decisions.

Multiple Myeloma Drugs Market Trends:

Rising Burden of Hematological Cancers Boosting Drug Demand

The increasing incidence of hematologic malignancies globally is significantly influencing the multiple myeloma drug market. In 2022, these cancers accounted for 6.6% of all diagnosed cancer cases and 7.2% of related deaths, underscoring the critical need for targeted therapies. As multiple myeloma stems largely from genetic abnormalities, its treatment requires a multidisciplinary approach involving immunomodulatory drugs, chemotherapy, radiation, and stem cell transplants. Platelet transfusions also play a role in managing side effects. With early detection improving, more patients are eligible for advanced treatments. Healthcare systems worldwide are under pressure to offer effective therapeutics, which is accelerating innovation and boosting investments in myeloma-specific drugs, thus contributing to the positive multiple myeloma drugs market outlook.

Technological Advancements Accelerating Treatment Innovations

Technological progress is transforming multiple myeloma treatment, particularly through innovations like microRNA-based therapies and nanomedicines. These platforms enable precision targeting of malignant cells while minimizing damage to healthy tissues. A prime example is Ardena's nanomedicine facility in Oss, Netherlands, which secured GMP certification in November 2024 after a €20 million investment. This facility supports complex manufacturing of lipid and polymeric nanoparticles, delivery vehicles critical for transporting macromolecular agents to the bone marrow and triggering antitumor responses. Such innovations not only enhance treatment outcomes but also lower long-term healthcare costs by reducing complications. As pharmaceutical companies expand their nanotech capabilities, these developments are expected to play a vital role in driving the multiple myeloma drug market growth.

Increasing Biologic Therapy Adoption and Healthcare Spending

Growing awareness about biologic therapies is reshaping treatment preferences in the multiple myeloma landscape. These drugs leverage the immune system to recognize and eliminate cancer cells, offering a less invasive and often more effective alternative to conventional treatments. Patients are increasingly drawn to therapies that provide targeted mechanisms with fewer systemic side effects. Alongside this trend, rising global healthcare expenditures, reported at USD 9.8 Trillion in 2021, equating to 10.3% of global GDP, are enabling wider access to these advanced treatments. Combined with the pharmaceutical industry's expanding research budgets, biologic therapies are gaining traction across developed and emerging markets. This shift is expected to significantly contribute to the expansion of the multiple myeloma drug market in the coming years.

Multiple Myeloma Drugs Industry Segmentation:

Analysis by Therapy:

  • Targeted Therapy
  • Biologic Therapy
  • Chemotherapy
  • Others

Targeted therapy plays a pivotal role in the multiple myeloma drug market by offering a precision-based approach that directly interferes with specific molecules responsible for cancer cell growth and survival. These therapies, such as proteasome inhibitors and histone deacetylase inhibitors, provide enhanced efficacy with fewer side effects compared to traditional treatments. The increasing understanding of the genetic and molecular mechanisms of multiple myeloma has led to the development of more selective drugs. Ongoing clinical trials and regulatory approvals are further accelerating adoption. Moreover, the ability of targeted therapy to be used in combination regimens is expanding its clinical utility, driving consistent growth in this segment globally.

Biologic therapy has gained significant prominence in the multiple myeloma drug market, largely due to its ability to harness the body's immune system to combat cancer. Monoclonal antibodies, such as daratumumab and elotuzumab, have shown strong clinical success by targeting specific proteins on myeloma cells. The increasing acceptance of immunotherapy approaches and the growing demand for personalized medicine are key growth drivers for this segment. With rising awareness among healthcare providers and patients regarding the benefits of biologics, coupled with supportive reimbursement frameworks and expanding biologics pipelines, the segment is expected to experience sustained growth in both developed and emerging markets.

Chemotherapy continues to serve as a foundational component in the treatment of multiple myeloma, particularly in combination with other therapeutic classes. Although its prominence has somewhat declined with the emergence of targeted and biologic therapies, chemotherapy remains essential, especially in newly diagnosed or relapsed patients requiring rapid cytoreduction. The wide availability, proven efficacy, and cost-effectiveness of chemotherapeutic agents ensure their continued use. Advancements in formulation, including oral chemotherapies and supportive care options to manage side effects, have also contributed to maintaining its relevance. As part of combination regimens, chemotherapy enhances overall treatment outcomes, securing its ongoing role in the evolving multiple myeloma drug market.

Analysis by Drug Type:

  • Immunomodulatory Drugs
  • Proteasome Inhibitors
  • Histone Deacetylase Inhibitors
  • Monoclonal Antibody Drugs
  • Steroids
  • Others

Immunomodulatory drugs stand as the largest drug type in 2024, holding around 38.7% of the market. The immunomodulatory drugs segment dominates the multiple myeloma drug market due to its proven effectiveness in enhancing immune responses and directly targeting cancer cells. These drugs, such as lenalidomide and pomalidomide, have become foundational therapies for both newly diagnosed and relapsed patients, often used in combination with other treatments like corticosteroids and proteasome inhibitors. Their ability to modulate the tumor microenvironment, suppress abnormal plasma cells, and improve patient outcomes has led to widespread adoption. Additionally, ongoing clinical trials and regulatory approvals continue to expand their indications, reinforcing their central role in treatment protocols and sustaining their dominance in the multiple myeloma drug market.

Analysis by End User:

  • Men
  • Women

Men represent a significant segment in the multiple myeloma drug market, accounting for a higher prevalence rate compared to women. Epidemiological data indicate that men are more frequently diagnosed with multiple myeloma, which naturally drives greater demand for therapeutic interventions among this demographic. The higher incidence may be attributed to genetic, hormonal, and lifestyle factors, including greater exposure to environmental risk elements such as industrial chemicals and tobacco use. As a result, pharmaceutical companies and healthcare providers often prioritize this patient group in clinical trials and treatment planning. Increased health awareness, along with access to advanced diagnostics and treatment options, further supports the growth of this segment within the market.

Women constitute an essential and growing segment in the multiple myeloma drug market, supported by rising awareness and improving access to healthcare. Though the prevalence of multiple myeloma is relatively lower among women compared to men, the market demand from this group is expanding due to early diagnosis and increasing participation in screening programs. Advances in gender-specific research and the growing focus on tailoring therapies to address women's physiological responses contribute to better treatment outcomes. Additionally, supportive care services and educational initiatives have improved adherence to treatment regimens among female patients, fueling continued market growth in this segment.

Analysis by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Hospital pharmacies lead the market with around 57.0% of market share in 2024. The hospital pharmacies segment dominates the multiple myeloma drug market due to the complex nature of treatment regimens and the need for specialized administration and monitoring. Multiple myeloma therapies often involve intravenous drugs, combination treatments, and biologics that require hospital-grade infrastructure and professional supervision. Hospitals serve as primary points for cancer diagnosis, staging, and early treatment, making them central to drug dispensing and patient management. Furthermore, hospital pharmacies maintain a broader inventory of high-cost and high-risk oncology drugs, ensuring immediate access for patients undergoing intensive therapies. This central role in comprehensive cancer care reinforces their dominance in the multiple myeloma drug market.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2024, North America accounted for the largest market share of over 40.7%. North America dominates the multiple myeloma drug market due to its advanced healthcare infrastructure, high healthcare spending, and robust presence of leading pharmaceutical companies engaged in oncology research. The region benefits from early adoption of innovative therapies, strong regulatory support from agencies like the FDA, and widespread access to cutting-edge treatments. A high prevalence of multiple myeloma, combined with increased awareness and early diagnosis, contributes to the growing demand for targeted and biologic therapies. Additionally, favorable reimbursement policies and significant investment in clinical trials further strengthen North America's leadership in this space, ensuring its continued prominence in the multiple myeloma drug market. For instance, in June 2024, AbbVie begun its Phase III CERVINO trial for ABBV-383, a bispecific T-cell engager targeting BCMA and CD3, in patients with relapsed/refractory multiple myeloma. The global, randomized trial will enroll 380 patients who have had at least two prior therapies but not BCMA-targeted ones. Participants will receive ABBV-383 or standard available therapies. The primary endpoints are progression-free survival and overall response rate, with secondary measures including survival and disease symptom changes. ABBV-383 is dosed monthly to simplify treatment.

Key Regional Takeaways:

United States Multiple Myeloma Drugs Market Analysis

In 2024, the United States held a market share of over 86.8% in North America. The United States multiple myeloma drug market is primarily driven by the rising incidence of the disease, supported by improved diagnostic techniques that enable earlier detection and intervention. In 2025, the American Cancer Society projected approximately 36,110 new cases of multiple myeloma in the U.S. (20,030 in men, 16,080 in women) and about 12,030 related deaths (6,540 in men, 5,490 in women). In accordance with this, robust advancements in immunotherapy and precision medicine are fostering the development of novel drug classes and combination regimens, thereby impelling the market. The growing presence of a robust clinical trial pipeline, pushed by industry-academic collaborations, is further propelling market growth. Similarly, the growing awareness among healthcare providers and patients regarding early treatment options is enhancing adoption rates. Additionally, the market is benefiting from strategic mergers, acquisitions, and partnerships that strengthen research capabilities and expand portfolios. Apart from this, continued investments in biomarker-driven research and personalized medicine are driving targeted drug development and market expansion.

Europe Multiple Myeloma Drugs Market Analysis

The multiple myeloma drug market in Europe is experiencing growth due to the region's aging population, which elevates the prevalence of hematologic cancers requiring advanced treatments. It has been reported that Europe's median age is projected to rise by 5.5 years, from 44.7 in 2024 to 50.2 in 2100, with the share of people aged 80 and above expected to grow from 6.1% to 15.3%. In line with this, continued improvements in healthcare infrastructure across Europe are enhancing market accessibility. Similarly, the expansion of national cancer control programs, which promote earlier detection and the establishment of structured care pathways, is fostering market expansion. The increase in government funding dedicated to research on rare and complex diseases is driving pharmaceutical innovation. Additionally, the increasing acceptance of biosimilars is reducing treatment costs and expanding patient access to these therapies. Furthermore, the growing integration of digital health tools and electronic medical records, which improves personalized treatment planning and monitoring, is stimulating market appeal. Besides this, cross-border healthcare collaboration within the EU is strengthening knowledge exchange and accelerating the adoption of advanced multiple myeloma therapies across member states.

Asia Pacific Multiple Myeloma Drugss Market Analysis

The Asia Pacific market is largely driven by rising healthcare spending in emerging economies, which strengthens access to advanced oncology therapies. An industry report projected that India's healthcare spending will increase from 3.3% to 5% of GDP by 2030. Furthermore, rapid urbanization and changing lifestyles are increasing cancer prevalence, thereby strengthening market demand. The strong government initiatives to raise awareness of rare diseases and improve patient registries, which support early diagnosis and timely care, are bolstering market development. Additionally, strategic collaborations between regional biotech companies and global pharmaceutical firms are accelerating the transfer of technology and innovative drug development. The expansion of specialized cancer treatment centers and the growth of medical tourism infrastructure are attracting patients seeking advanced therapies. As such, India's medical tourism sector is expected to grow at a double-digit rate of 14-15% following the recent relaxation of visa rules outlined in the Union Budget 2025-26. Moreover, broader reimbursement coverage and regulatory reforms across key Asia-Pacific countries are facilitating the faster approval and availability of cutting-edge multiple myeloma treatments, thereby providing an impetus to the market.

Latin America Multiple Myeloma Drugss Market Analysis

In Latin America, the multiple myeloma drug market is growing due to the steady improvement of healthcare systems and greater public funding for oncology services across the region. Accordingly, by March 2025, Brazil's radiotherapy expansion plan, with Varian, added 92 linacs and nine HDR afterloaders, reducing wait times and enabling advanced treatments. The initiative now treats an estimated 55,000 cancer patients annually, expanding access nationwide. In addition to this, rising awareness initiatives and patient advocacy programs are encouraging earlier diagnosis and improved treatment uptake. The increasing presence of multinational pharmaceutical companies, through the formation of strategic partnerships and expansion of distribution channels, is bolstering market development. Furthermore, wider participation in international clinical trials is fostering scientific exchange and supporting faster access to advanced multiple myeloma therapies, thereby creating lucrative market opportunities.

Middle East and Africa Multiple Myeloma Drugs Market Analysis

The market in the Middle East and Africa is significantly influenced by rising healthcare expenditure and strong government initiatives to modernize oncology care. Industry analysis indicates that the UAE's healthcare spending ranks among the highest per capita globally, at approximately USD 1,200. The sector generates over USD 4.63 Billion in annual revenue and comprises 75 insurers, which provide more than 12,000 policies. Similarly, the continual development of regional cancer centers is expanding access to specialized diagnostics and advanced treatment options for multiple myeloma. Furthermore, increasing collaborations between local healthcare systems and global pharmaceutical companies are enhancing the market reach. Similarly, the growth of public-private partnerships and focused investments in training medical professionals is strengthening the oncology workforce, ensuring that patients receive high-quality, up-to-date care and improving overall treatment outcomes.

Competitive Landscape:

The competitive landscape of the multiple myeloma drug market is characterized by intense R&D activity, strategic collaborations, and continuous drug innovation. Leading players are focusing on expanding their product pipelines through the development of advanced biologics, immunotherapies, and targeted treatments. For instance, in June 2025, Glenmark's subsidiary, Ichnos Glenmark Innovation (IGI), reported promising early trial results for its cancer drug ISB 2001, targeting relapsed/refractory multiple myeloma. The novel trispecific antibody therapy showed a 79% overall response rate (ORR) among heavily pretreated patients, with 30% achieving complete or near-complete response. Six of eight patients tested negative for minimal residual disease. The trial, presented at ASCO 2025, showed manageable side effects and is moving into dose expansion to determine optimal dosing for broader testing. Regulatory approvals and fast-track designations are accelerating the launch of novel therapeutics, while mergers and licensing agreements are enhancing global reach and capabilities. Companies are increasingly investing in technologies such as CAR-T cell therapies and nanomedicine-based delivery systems to gain a competitive edge. With rising competition and robust clinical pipelines, the multiple myeloma drugs market forecast projects sustained innovation and market expansion through 2033, driven by unmet medical needs and a growing patient population worldwide.

The report provides a comprehensive analysis of the competitive landscape in the multiple myeloma drug market with detailed profiles of all major companies, including:

  • Amgen Inc.
  • Bristol Myers Squibb
  • Daiichi Sankyo Co., Ltd.
  • Sanofi-Aventis Groupe (Genzyme Corporation)
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • PHARMA MAR, S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

  • 1.How big is the multiple myeloma drug market?
  • 2.What is the future outlook of multiple myeloma drug market?
  • 3.What are the key factors driving the multiple myeloma drug market?
  • 4.Which region accounts for the largest multiple myeloma drug market share?
  • 5.Which are the leading companies in the global multiple myeloma drug market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Pipeline Assesment/Clinical Trial Products/Clinical Developments

  • 5.1 PegIntron (Pegylated interferon alfa-2b)
  • 5.2 Pomalidomide
  • 5.3 Tanespimycin (KOS-953)
  • 5.4 MLN 9708
  • 5.5 SRT-501- 012
  • 5.6 BHQ880
  • 5.7 Panobinostat
  • 5.8 ZIO-101
  • 5.9 VEGF-Trap(Aflibercept)
  • 5.10 Denosumab
  • 5.11 Perifosine
  • 5.12 Actimid (CC-5013)
  • 5.13 Romidepsin
  • 5.14 Plitidepsin (Aplidin)
  • 5.15 Temsirolimus (Torisel)
  • 5.16 Sorafenib
  • 5.17 Bevacizumab

6 Global Multiple Myeloma Drugs Market

  • 6.1 Market Overview
  • 6.2 Market Performance
  • 6.3 Impact of COVID-19
  • 6.4 Market Forecast

7 Market Breakup by Therapy

  • 7.1 Targeted Therapy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Biologic Therapy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Chemotherapy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Drug Type

  • 8.1 Immunomodulatory Drugs
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Proteasome Inhibitors
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Histone Deacetylase Inhibitors
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Monoclonal Antibody Drugs
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Steroids
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by End-User

  • 9.1 Men
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Women
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Retail Pharmacies
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Online Pharmacies
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Others
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Indicators

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Amgen Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Bristol Myers Squibb
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
      • 16.3.2.4 SWOT Analysis
    • 16.3.3 Daiichi Sankyo Co.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4 Sanofi-Aventis Groupe (Genzyme Corporation)
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 SWOT Analysis
    • 16.3.5 Johnson & Johnson Services, Inc.
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 Merck & Co., Inc.
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 Novartis International AG
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis
    • 16.3.8 Pfizer Inc.
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9 PHARMA MAR, S.A.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
    • 16.3.10 Takeda Pharmaceutical Company Limited.
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
      • 16.3.10.3 Financials
      • 16.3.10.4 SWOT Analysis
    • 16.3.11 Teva Pharmaceutical Industries Ltd.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
      • 16.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Multiple Myeloma Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Multiple Myeloma Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Multiple Myeloma Drugs Market: Breakup by Therapy (in %), 2024
  • Figure 4: Global: Multiple Myeloma Drugs Market: Breakup by Drug Type (in %), 2024
  • Figure 5: Global: Multiple Myeloma Drugs Market: Breakup by End-User (in %), 2024
  • Figure 6: Global: Multiple Myeloma Drugs Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Multiple Myeloma Drugs Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Multiple Myeloma Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 9: Global: Multiple Myeloma Drugs (Targeted Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Multiple Myeloma Drugs (Targeted Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Multiple Myeloma Drugs (Biologic Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Multiple Myeloma Drugs (Biologic Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Multiple Myeloma Drugs (Chemotherapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Multiple Myeloma Drugs (Chemotherapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Multiple Myeloma Drugs (Immunomodulatory Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Multiple Myeloma Drugs (Immunomodulatory Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Multiple Myeloma Drugs (Proteasome Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Multiple Myeloma Drugs (Proteasome Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Multiple Myeloma Drugs (Histone Deacetylase Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Multiple Myeloma Drugs (Histone Deacetylase Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Multiple Myeloma Drugs (Monoclonal Antibody Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Multiple Myeloma Drugs (Monoclonal Antibody Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Multiple Myeloma Drugs (Steroids) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Multiple Myeloma Drugs (Steroids) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Multiple Myeloma Drugs (Men) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Multiple Myeloma Drugs (Men) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Multiple Myeloma Drugs (Women) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Multiple Myeloma Drugs (Women) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Multiple Myeloma Drugs (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Multiple Myeloma Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Multiple Myeloma Drugs (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Multiple Myeloma Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Multiple Myeloma Drugs (Online Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Multiple Myeloma Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: North America: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: North America: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: United States: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: United States: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Canada: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Canada: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Asia Pacific: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Asia Pacific: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: China: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: China: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Japan: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Japan: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: India: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: India: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: South Korea: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: South Korea: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Australia: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Australia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Indonesia: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Indonesia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Others: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Europe: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Europe: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Germany: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Germany: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: France: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: France: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: United Kingdom: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: United Kingdom: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Italy: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Italy: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Spain: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Spain: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Russia: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Russia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Others: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Latin America: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Latin America: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Brazil: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Brazil: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Mexico: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Mexico: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Others: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Middle East and Africa: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 88: Middle East and Africa: Multiple Myeloma Drugs Market: Breakup by Country (in %), 2024
  • Figure 89: Middle East and Africa: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 90: Global: Multiple Myeloma Drugs Industry: SWOT Analysis
  • Figure 91: Global: Multiple Myeloma Drugs Industry: Value Chain Analysis
  • Figure 92: Global: Multiple Myeloma Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Multiple Myeloma Drugs Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Therapy (in Million USD), 2025-2033
  • Table 3: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 4: Global: Multiple Myeloma Drugs Market Forecast: Breakup by End-User (in Million USD), 2025-2033
  • Table 5: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 6: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Multiple Myeloma Drugs Market Structure
  • Table 8: Global: Multiple Myeloma Drugs Market: Key Players